660 related articles for article (PubMed ID: 31916329)
1. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
Packer M
Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
[TBL] [Abstract][Full Text] [Related]
2. Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Packer M
Am J Nephrol; 2020; 51(4):289-293. PubMed ID: 32126558
[TBL] [Abstract][Full Text] [Related]
3. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Packer M
J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
[TBL] [Abstract][Full Text] [Related]
4. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
Packer M
Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
6. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes.
Packer M
J Diabetes Complications; 2020 Sep; 34(9):107647. PubMed ID: 32534886
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
8. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
Poursharif S; Hamza S; Braam B
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective Effects of SGLT2 Inhibitors.
Vallon V
Heart Fail Clin; 2022 Oct; 18(4):539-549. PubMed ID: 36216484
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
Ravindran S; Munusamy S
J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
[TBL] [Abstract][Full Text] [Related]
12. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
Packer M
Circulation; 2022 Nov; 146(18):1383-1405. PubMed ID: 36315602
[TBL] [Abstract][Full Text] [Related]
13. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
14. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
15. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
16. Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors.
Packer M
Eur J Heart Fail; 2020 Apr; 22(4):618-628. PubMed ID: 32037659
[TBL] [Abstract][Full Text] [Related]
17. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
18. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
19. Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells.
Guo Y; Ran Z; Zhang Y; Song Z; Wang L; Yao L; Zhang M; Xin J; Mao X
Biomed Pharmacother; 2020 Nov; 131():110684. PubMed ID: 33152903
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M; Cherney DZ
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
